2022
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery
Phung M, Webb P, DeFazio A, Fereday S, Lee A, Bowtell D, Fasching P, Goode E, Goodman M, Karlan B, Lester J, Matsuo K, Modugno F, Brenton J, Van Gorp T, Pharoah P, Schildkraut J, McLean K, Meza R, Mukherjee B, Richardson J, Grout B, Chase A, Deurloo C, Terry K, Hanley G, Pike M, Berchuck A, Ramus S, Pearce C, Consortium O. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. Gynecologic Oncology 2022, 168: 68-75. PMID: 36401943, PMCID: PMC10398872, DOI: 10.1016/j.ygyno.2022.10.018.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerEstrogen-only therapyPrimary cytoreductive surgeryMacroscopic residual diseaseResidual diseaseParous womenFamily history of ovarian cancerOvarian Cancer Association ConsortiumMenopausal hormone therapy useHistory of ovarian cancerFirst-degree family historyCytoreductive surgeryOvarian cancer riskOvarian cancerAdvanced stage high-grade serous ovarian cancerPresence of macroscopic residual diseaseHormone therapy useHigh-grade serous ovarian cancer patientsDepot medroxyprogesterone acetate useBody mass indexLogistic regression modelsOral contraceptive useIncomplete pregnanciesSerous ovarian cancerFactors influencing survival
2021
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association
Khoja L, Weber RP, Group T, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology 2021, 164: 195-201. PMID: 34776242, PMCID: PMC9444325, DOI: 10.1016/j.ygyno.2021.10.088.Peer-Reviewed Original ResearchConceptsHistory of endometriosisOvarian cancer riskEPT useOvarian Cancer Association ConsortiumOvarian cancerInverse associationOdds ratioCancer riskCancer associationInvasive epithelial ovarian cancerHormone therapy useMenopausal hormone therapyEpithelial ovarian cancerCase-control studyConfidence intervalsSlight inverse associationWarrants further investigationHormone therapyTherapy usePooled analysisEndometriosisHysterectomyCancerTherapySelf-reported dataDepot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk
Phung M, Lee A, Wu A, Berchuck A, Cho K, Cramer D, Doherty J, Goodman M, Hanley G, Harris H, McLean K, Modugno F, Moysich K, Mukherjee B, Schildkraut J, Terry K, Titus L, Consortium O, Jordan S, Webb P, Consortium O, Pike M, Pearce C. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 927-935. PMID: 33619020, PMCID: PMC9281627, DOI: 10.1158/1055-9965.epi-20-1355.Peer-Reviewed Original ResearchConceptsOvarian cancer riskDepot medroxyprogesterone acetate useRisk of ovarian cancerDepot medroxyprogesterone acetateCancer riskOvarian cancerDecreased riskInverse associationRisk of invasive epithelial ovarian cancerRisk of ovarian cancer overallAssociated with decreased risk of ovarian cancerDecreased risk of ovarian cancerOvarian Cancer Association ConsortiumDecreased ovarian cancer riskSystematic reviewOvarian cancer overallInvasive epithelial ovarian cancerAssociated with decreased riskCombined oral contraceptive useInjectable progestin-only contraceptivesProgestin-only contraceptive useProgestin-releasing intrauterine deviceContraceptive useAssociated with ovarian cancerProgestin-only contraceptives
2020
Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies
Lee AW, Rosenzweig S, Wiensch A, Group T, Ramus SJ, Menon U, Gentry-Maharaj A, Ziogas A, Anton-Culver H, Whittemore AS, Sieh W, Rothstein JH, McGuire V, Wentzensen N, Bandera EV, Qin B, Terry KL, Cramer DW, Titus L, Schildkraut JM, Berchuck A, Goode EL, Kjaer SK, Jensen A, Jordan SJ, Ness RB, Modugno F, Moysich K, Thompson PJ, Goodman MT, Carney ME, Chang-Claude J, Rossing MA, Harris HR, Doherty JA, Risch HA, Khoja L, Alimujiang A, Phung MT, Brieger K, Mukherjee B, Pharoah PDP, Wu AH, Pike MC, Webb PM, Pearce CL. Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal Of The National Cancer Institute 2020, 113: 301-308. PMID: 32766851, PMCID: PMC7936053, DOI: 10.1093/jnci/djaa099.Peer-Reviewed Original ResearchConceptsOvarian cancer riskInvasive epithelial ovarian cancerClear cell ovarian cancerIncomplete pregnanciesEpithelial ovarian cancerOvarian cancerOvarian Cancer Association ConsortiumCancer riskOdds ratioInvasive epithelial ovarian cancer casesEpithelial ovarian cancer casesHistotype-specific analysesHistotype-specific associationsOral contraceptive useInvasive ovarian cancerHistory of breastfeedingConfidence intervalsOvarian cancer casesCase-control studyOCAC studiesMajor histotypesPooled analysisInverse associationCancer casesComplete pregnancy
2017
Explaining Disparities in Ovarian Cancer Incidence Rates between Women of African and European Ancestry: The Role of Genetic Factors
Mullins M, Mukherjee B, Wu A, Pike M, Pharoah P, Berchuck A, Pearce C. Explaining Disparities in Ovarian Cancer Incidence Rates between Women of African and European Ancestry: The Role of Genetic Factors. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 433-434. DOI: 10.1158/1055-9965.epi-17-0030.Peer-Reviewed Original ResearchGenetic risk scoreOvarian cancer incidence ratesNon-Hispanic White (NHWPopulation attributable risk percentCollaborative Oncological Gene-environment StudyCancer incidence ratesNon-genetic risk factorsIncidence rateAfrican AmericansAssociated with ovarian cancer riskOvarian Cancer Association ConsortiumOophorectomy ratesRisk of ovarian cancerAncestry groupsOvarian cancer riskAttributable risk percentNon-genetic riskGene-environment studiesOvarian cancerSingle nucleotide polymorphismsRisk factorsConditional logistic regressionGRS quintileRisk percentLowest quintile
2016
A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer
Lee A, Bomkamp A, Bandera E, Jensen A, Ramus S, Goodman M, Rossing M, Modugno F, Moysich K, Chang‐Claude J, Rudolph A, Gentry‐Maharaj A, Terry K, Gayther S, Cramer D, Doherty J, Schildkraut J, Kjaer S, Ness R, Menon U, Berchuck A, Mukherjee B, Roman L, Pharoah P, Chenevix‐Trench G, Olson S, Hogdall E, Wu A, Pike M, Stram D, Pearce C, Consortium F. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. International Journal Of Cancer 2016, 139: 2646-2654. PMID: 27420401, PMCID: PMC5500237, DOI: 10.1002/ijc.30274.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAllelesAlternative SplicingCase-Control StudiesDisease SusceptibilityEstrogen Replacement TherapyFemaleGene-Environment InteractionGenome-Wide Association StudyGenotypeHumansMenopauseMiddle AgedOdds RatioOvarian NeoplasmsPolymorphism, Single NucleotidePopulation SurveillanceRiskTelomeraseConceptsOvarian Cancer Association ConsortiumEstrogen-alone therapyOvarian cancer riskEndometrioid ovarian cancerOvarian cancerET usersET useT alleleAssociated with ovarian cancer riskCancer riskLong-term ET usersOvarian cancer susceptibility lociRisk of ovarian cancerSusceptibility variantsMenopausal estrogen therapyCancer susceptibility lociSerous ovarian cancerSplice variantsNon-usersCase-control studyConditional logistic regressionGenome-wide association studiesIncreased risk of diseaseEndometrioid histotypeEstrogen therapy